Phase 2 Asthma Trial, Recruiting NCT07301255 Sponsor: Enveda Therapeutics Condition: Asthma
Back to Asthma

Phase 2 Asthma Trial, Recruiting

NCT07301255
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to read, understand, and sign a consent form before any study activities begin
  • Adults between 18 and 75 years old who have been diagnosed by a doctor with moderate to severe asthma for at least 12 months
  • People whose asthma treatment has been stable on a combination of an inhaled steroid and a long-acting reliever inhaler for at least 2 months before the screening visit
  • People whose lung function test results (measured before using a reliever inhaler) fall within a specific range at both the screening and baseline visits (confirm with trial site)
  • People whose lungs show a measurable improvement in airflow after using a reliever inhaler during testing
  • People whose asthma symptom questionnaire score falls within a specific range at both the screening and baseline visits (confirm with trial site)
  • People who have had at least one asthma flare-up in the past 12 months that needed steroid tablets or injections, or required a hospital or emergency visit

Who may not be able to join:

  • People who had a moderate or severe asthma flare-up within the 4 weeks before screening
  • People with a history of life-threatening asthma
  • People with another serious lung or breathing condition
  • People who have had a bronchial thermoplasty procedure (a type of airway treatment) within the past 2 years
  • People with another illness that is not well controlled
  • People who have used biologic medicines for asthma within the past 6 months (or within a certain timeframe based on the specific medicine)
  • People who regularly need medicines that suppress the immune system, or who frequently need steroid tablets or injections
  • People who currently smoke, or former smokers with a significant smoking history
  • People with high blood pressure that is not well controlled
  • People with significant liver problems

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Enveda Therapeutics
Registry
ClinicalTrials.gov
Start date
9 January 2026
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence and Severity of Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov